TBPH · Theravance Biopharma, Inc. · Executive Compensation
Market Cap
$883.66M
Shares
51.92M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jeremy Grant | Class II director | Appointed | 2023-12-21 |
| Áine Miller | SVP, Development | Appointed | 2023-11-07 |
| Deepika R. Pakianathan | Class III director | Appointed | 2023-05-03 |
| Dean J. Mitchell | Class III director | Appointed | 2023-05-03 |
| James C. Kelly | Class I member of the Board | Appointed | 2023-04-11 |